homeostasis/metabolism phenotype

• hyperglycemia
  • in streptozotocin-treated (STZ) mice (to induce diabetes), serum glucose is significantly increased compared to untreated mutant or wild-type controls
  (MGI Ref ID J:127478)

• decreased circulating cholesterol level
  • mean levels are significantly lower than in wild-type controls and STZ-treated mutants
  (MGI Ref ID J:127478)

• increased blood urea nitrogen level
  • STZ-treated mutants show elevated BUN levels compared to untreated mice, but levels are comparable to STZ-treated wild-type
  (MGI Ref ID J:127478)

mammalian phenotype

• homeostasis/metabolism phenotype
  • Normal - mice do not develop significant albuminuria after 6 months of streptozotocin (STZ) -induced diabetes
  (MGI Ref ID J:127478)

renal/urinary system phenotype

• abnormal kidney morphology
  • total kidney collagen in STZ-treated mice increases only 8% compared to 40% in treated wild-type
  (MGI Ref ID J:127478)

• abnormal renal glomerulus morphology
  • ed 64% relative to untreated wild-type mice
  (MGI Ref ID J:127478)
  • glomerular extracellular matrix (ECM) area is greater than in wild-type controls; however, when expressed as fractional glomerular ECM area, little difference is observed between any genotype
  (MGI Ref ID J:127478)
  • glomerular extracellular matrix (ECM) area is significantly higher compared to controls; after 6 months of STZ-induced diabetes, ECM area is decreased 15% compared to Serpine1 single deficient mice while in STZ-treated wild-type mice, ECM area is increased 64% relative to untreated wild-type mice
  (MGI Ref ID J:127478)

adipose tissue phenotype

• abnormal epididymal fat pad morphology
  • after 12 weeks on a high fat diet, epididymal fat pad was only 25% of wild-type
  (MGI Ref ID J:87982)

• decreased subcutaneous adipose tissue amount
  • subcutaneous white fat pad mass was also reduced
  (MGI Ref ID J:87982)

homeostasis/metabolism phenotype

• decreased circulating interleukin-6 level
  • plasma levels are markedly reduced at 8 hours after turpentine injection
  (MGI Ref ID J:133227)

• increased body temperature
  • increased on a high fat diet
  (MGI Ref ID J:87982)

• abnormal enzyme/coenzyme activity
  • after 8 hours, myeloperoxidase (MPO) activity is higher in mutants in hind limb homogenates than in wild-type
  (MGI Ref ID J:133227)

• abnormal interleukin level
  • local Il6 levels in injured tissue at 8 hours post-injection are lower than in controls
  (MGI Ref ID J:133227)

• decreased liver triglyceride level
  • lower levels after 12 weeks on a high fat diet
  (MGI Ref ID J:87982)

• decreased triglyceride level
  • lower levels in both skeletal muscle and liver after 12 weeks on a high fat diet
  (MGI Ref ID J:87982)

• abnormal energy expenditure
  • increased after 12 weeks on a high fat diet
  (MGI Ref ID J:87982)

• enhanced wound healing
  • thickened epidermal layer found within newly healed wounds
  (MGI Ref ID J:72394)
  • dermal incisions healed more rapidly than normal
  (MGI Ref ID J:72394)

• increased urine protein level
  • an earlier enhancement of protein urea
  (MGI Ref ID J:85989)

• increased oxygen consumption
  • after 12 weeks on a high fat diet, oxygen consumption is increased
  (MGI Ref ID J:87982)

immune system phenotype

• abnormal acute inflammation
  • in mutants after turpentine injection, serum amyloid P and C3 are significantly lower at 24 hours compared to wild-type and display a delayed peak at 3 days after injection
  (MGI Ref ID J:133227)
  • Normal - haptoglobin levels do not differ from wild-type at any time after turpentine injection
  (MGI Ref ID J:133227)
  • C3 peak levels at day 3 are higher than in wild-type
  (MGI Ref ID J:133227)

• decreased circulating interleukin-6 level
  • plasma levels are markedly reduced at 8 hours after turpentine injection
  (MGI Ref ID J:133227)

• increased granulocyte number
  • relative to controls following turpentine injection
  (MGI Ref ID J:133227)

• abnormal interleukin level
  • local Il6 levels in injured tissue at 8 hours post-injection are lower than in controls
  (MGI Ref ID J:133227)

• respiratory system inflammation
  • inflammation induced fibrosis in the lung occurs at a much slower rate
  (MGI Ref ID J:66093)
  • fibrin content of lungs reduced generally
  (MGI Ref ID J:66093)
  • survival is better
  (MGI Ref ID J:66093)

• glomerulonephritis
  • increased mortality
  (MGI Ref ID J:85989)
  • increased thrombin production
  (MGI Ref ID J:85989)
  • higher incidence of fibrin positive crescents
  (MGI Ref ID J:85989)
  • increased infiltration of injury with CD4+ T cells
  (MGI Ref ID J:85989)

• increased acute inflammation
  • after turpentine injection to hind limb to induce tissue injury, 8 week-old mutants show significantly more local tissue injury compared to controls
  (MGI Ref ID J:133227)
  • treatment resulted in local abscess formation and neutrophilic granulocyte infiltration encapsulated by macrophages and fibroblasts
  (MGI Ref ID J:133227)

integument phenotype

• decreased subcutaneous adipose tissue amount
  • subcutaneous white fat pad mass was also reduced
  (MGI Ref ID J:87982)

liver/biliary system phenotype

• decreased liver triglyceride level
  • lower levels after 12 weeks on a high fat diet
  (MGI Ref ID J:87982)

mammalian phenotype

• immune system phenotype
  • Normal - chemokine levels in injured tissue are similar between mutants and controls, peaking at 1-3 days
  (MGI Ref ID J:133227)

• neoplasm
  • Normal - survival times after foot pad tumor removal are not significantly different among Serpine1-deficient, Serpine1-overexpressing transgenic, or wild-type mice
  (MGI Ref ID J:33232)
  • Normal - no significant differences are observed compared to controls in terms of primary tumor size of footpad tumors induced by foot pad injection with tumor cells at 10, 17, or 21 days post-injection
  (MGI Ref ID J:33232)
  • Normal - after injection of melanoma cells, number of primary pulmonary metastases post-injection, or tumor burdens initiated by injections of increasing doses of cells do not significantly differ from wild-type controls
  (MGI Ref ID J:33232)

• hematopoietic system phenotype
  • Normal - bleeding time was normal
  (MGI Ref ID J:39819)

renal/urinary system phenotype

• glomerular crescent
  • higher incidence of fibrin positive crescents
  (MGI Ref ID J:85989)

• glomerulonephritis
  • increased infiltration of injury with CD4+ T cells
  (MGI Ref ID J:85989)
  • increased mortality
  (MGI Ref ID J:85989)
  • increased thrombin production
  (MGI Ref ID J:85989)
  • higher incidence of fibrin positive crescents
  (MGI Ref ID J:85989)

• increased urine protein level
  • an earlier enhancement of protein urea
  (MGI Ref ID J:85989)

cardiovascular system phenotype

• decreased angiogenesis
  • neovascularization in general is reduced
  (MGI Ref ID J:65383)

• abnormal blood circulation
  • no fibrin present in the injured vessel walls
  (MGI Ref ID J:67531)
  • injury response in carotid arteries is reduced although cell proliferation in the adventitia is increased
  (MGI Ref ID J:67531)

respiratory system phenotype

• abnormal lung morphology
  • lung fibrin deposition following bleomycin treatment is almost undetectable compared to treated wild-type mice
  (MGI Ref ID J:31542)
  • no significant bleomycin-induced increase in lung collagen content is detected at 3 weeks posttreatment whereas treated wild-type mice show a significant increase in lung collagen; heterozygous mice are intermediate between null and wild-type in terms of collagen content
  (MGI Ref ID J:31542)
  • collagen content
  (MGI Ref ID J:31542)

• respiratory system inflammation
  • fibrin content of lungs reduced generally
  (MGI Ref ID J:66093)
  • inflammation induced fibrosis in the lung occurs at a much slower rate
  (MGI Ref ID J:66093)
  • survival is better
  (MGI Ref ID J:66093)

growth/size/body region phenotype

• abnormal body weight
  • less weight gain on a high fat diet than normal
  (MGI Ref ID J:87982)

• decreased body weight
  • at 2 weeks, mutants remain below initial body weight after turpentine injection-induced weight loss but wild-type mice recover and begin to gain weight around 6-7 days after injection
  (MGI Ref ID J:133227)

• weight loss
  • turpentine injection induces significant weight loss in mutants and wild-type mice in initial 2 days; however, after 2 days, wild-type animals start to recover body weight whereas mutants do not
  (MGI Ref ID J:133227)

hematopoietic system phenotype

• increased granulocyte number
  • relative to controls following turpentine injection
  (MGI Ref ID J:133227)

homeostasis/metabolism phenotype

• decreased sensitivity to xenobiotic induced morbidity/mortality
  • in mice treated with LPS
  (MGI Ref ID J:229191)

immune system phenotype

• decreased susceptibility to endotoxin shock
  • LPS-treated mice exhibit increased survival compared with wild-type mice
  (MGI Ref ID J:229191)

mortality/aging

• decreased sensitivity to xenobiotic induced morbidity/mortality
  • in mice treated with LPS
  (MGI Ref ID J:229191)

immune system phenotype

• increased susceptibility to Coronaviridae infection induced morbidity/mortality
  • mice infected with a lethal dose of SARS-CoV MA15 succumb to infection sooner than wild-type controls
  (MGI Ref ID J:288556)

• increased susceptibility to bacterial infection
  • following infection with S. pneumoniae, acute lung injury and alveolar hemorrhage is enhanced
  (MGI Ref ID J:124327)
  • following infection with live Streptococcus pneumoniae, S. pneumoniae wild-type lysate, and S. pneumoniae pneumolysin (PLY), mice begin to die earlier and are all dead by 5 days post-infection
  (MGI Ref ID J:124327)
  • following infection with S. pneumoniae strain ATCC 6303 (a more virulent strain), mortality is increased (10% survival compared to 45% in wild-type mice)
  (MGI Ref ID J:124327)

• increased susceptibility to Coronaviridae infection
  • SARS-CoV MA15-infected mice exhibit cuffing of inflammatory cells around the large airways and vasculature and mild interstitial membrane thickening and a few inflammatory cells in the alveolar spaces at 4 dpi, with moderate level of disease in the parenchyma by 7 dpi
  (MGI Ref ID J:288556)
  • Normal - however, virus load of SARS-CoV MA15-infected mice is similar to wild-type controls
  (MGI Ref ID J:288556)
  • mice infected with a sublethal dose of mouse-adapted SARS-CoV MA15 continue to lose weight through day 7 postinfection, showing more weight loss than wild-type controls at 5-7 days post infection (dpi), decreased locomotion, hunched posture, and labored breathing
  (MGI Ref ID J:288556)

• heart inflammation
  • older mutants exhibit significantly more macrophages in the heart
  (MGI Ref ID J:101486)

liver/biliary system phenotype

• liver fibrosis
  • 3 weeks after bile duct ligation (BDL), hepatic fibrosis is reduced 18-26% compared to wild-type; hepatic collagen content is similar to sham-operated wild-type
  (MGI Ref ID J:123733)

mammalian phenotype

• liver/biliary system phenotype
  • Normal - stellate cell activation, TGFbeta-1 and collagen synthesis are similar in mutants and controls before and after bile duct ligation
  (MGI Ref ID J:123733)

mortality/aging

• increased sensitivity to induced morbidity/mortality
  • following infection with S. pneumoniae strain ATCC 6303 (a more virulent strain), mortality is increased (10% survival compared to 45% in wild-type mice)
  (MGI Ref ID J:124327)
  • following infection with live Streptococcus pneumoniae, S. pneumoniae wild-type lysate, and S. pneumoniae pneumolysin (PLY), mice begin to die earlier and are all dead by 5 days post-infection
  (MGI Ref ID J:124327)

• increased susceptibility to Coronaviridae infection induced morbidity/mortality
  • mice infected with a lethal dose of SARS-CoV MA15 succumb to infection sooner than wild-type controls
  (MGI Ref ID J:288556)

respiratory system phenotype

• lung hemorrhage
  • SARS-CoV MA15-infected mice show increased lung hemorrhage at 7 dpi
  (MGI Ref ID J:288556)

cardiovascular system phenotype

• lung hemorrhage
  • SARS-CoV MA15-infected mice show increased lung hemorrhage at 7 dpi
  (MGI Ref ID J:288556)

• cardiac fibrosis
  • older mutants develop cardiac fibrosis, however fibrosis is not seen in the liver, spleen, lungs or kidneys and do not develop small vessel disease
  (MGI Ref ID J:101486)

• increased angiogenesis
  • aortic vessel explants show increased capillary sprouting in both collagen lattices and Matrigel
  (MGI Ref ID J:108675)

• heart inflammation
  • older mutants exhibit significantly more macrophages in the heart
  (MGI Ref ID J:101486)

homeostasis/metabolism phenotype

• abnormal enzyme/coenzyme activity
  • 3 weeks after BDL, pro-MMP-9 and MMP-9 activities in liver homogenates from mutants are increased significantly compared to wild-type controls
  (MGI Ref ID J:123733)
  • 3 weeks after BDL, urokinase plasminogen activator (uPA) and plasmin activity are not increased in mutants but tissue-type plasminogen activator (tPA) activity is significantly increased relative to wild-type
  (MGI Ref ID J:123733)